scholarly journals Viral, Serological, and Antioxidant Investigations of Equine Rhinitis A Virus in Serum and Nasal Swabs of Commercially Used Horses in Poland

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Barbara Bażanów ◽  
Agnieszka Frącka ◽  
Natalia Jackulak ◽  
Ewa Romuk ◽  
Tomasz Gębarowski ◽  
...  
Keyword(s):  
Nasal Swab ◽  
Virus Isolation ◽  
Serum Samples ◽  
Sod Activity ◽  
Nasal Swabs ◽  
Antioxidant Parameters ◽  
Antibody Titers ◽  
Group 2 ◽  
Positive Results ◽  
Group 1

Background. Equine rhinitis A virus (ERAV) is considered to be an important pathogen in horses, but relatively few studies are available.Aims. The purpose of this study was to verify ERAV seroprevalence in selected horses in Poland, in addition to correlation between ERAV and age and sex of analysed animals and the antioxidant status.Methods. The material collected from clinically healthy horses was tested using the VNT (353 serum samples) and virus isolation method (44 nasal swabs). 27 serum samples with antibody titers between 0 and ≥1 : 2048 were chosen for further analysis. The study was conducted in group 1 (ERAV titer ≤ 64) and group 2 (ERAV titer > 64).Results. Seroneutralisation tests showed positive results in 72% of serum samples. No significant correlation between ERAV seropositive results and selected biochemical indicators was observed. Group 2 had statistically higher concentrations of SOD and CuZnSOD than the analysed group 1.Conclusions. ERAV was not detected in the nasal swab samples. Antioxidant parameters did not significantly vary between horses of different breed, sex, or age. The ERAV virus had an impact on plasma total SOD and Cu/Zn SOD activity in horses in early stages of convalescence.

scholarly journals A comparison between different anti-retroviral therapy regimes on soluble inflammation markers: a pilot study

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Martina Maritati ◽  
Trentini Alessandro ◽  
Nunzia Zanotta ◽  
Manola Comar ◽  
Tiziana Bellini ◽  
...  
Keyword(s):  
Drug Regimen ◽  
Antiretroviral Drugs ◽  
Serum Samples ◽  
The Third ◽  
Cytokines And Chemokines ◽  
Antiretroviral Drug ◽  
Group 3 ◽  
Group 2 ◽  
Inflammatory Profile ◽  
Group 1

Abstract Background Although HIV-related deaths have decreased dramatically following the introduction of antiretroviral therapy (ART), HIV infection itself causes increased morbidity and mortality for both non-AIDS-related events or chronic inflammation and immune activation. The use of certain antiretroviral drugs can contribute to this process. Methods We investigated 26 potential biomarkers in serum samples from HIV-1 infected patients virologically suppressed under ART. The main objective of our study was to evaluate if virological suppression achieved with a triple drug regimen containing tenofovir disoproxil fumarate co-formulated with emtricitabine (TDF/FTC) as backbone, could correlate with a better immunological and inflammatory profile in relation to the third class of antiretroviral drug administered. The eligible patients were then divided into 3 groups in relation to the third drug associated with TDF/FTC: nucleoside reverse transcriptase inhibitors (NNRTI) (Group 1, n = 16), protease inhibitors (PI) (Group 2, n = 17) and integrase inhibitors (INI) (Group 3, n = 16). Results Inflammatory cytokines and chemokines were more represented in Group 2 than in Group 3 (IL-1Ra, p = 0.013; IL-12p70 p = 0.039; TNF-α p = 0.041; IL-8, p = 0.027; MIP1 β, p = 0.033). Eotaxin showed lower levels in Group 1 compared to Group 2 (p = 0.010), while IP-10 was significantly lower in Group 1 compared to both Group 2 and Group 3 (p = 0.003 and p = 0.007, respectively). Conclusions Our results seem to discourage the administration of PI as a third drug in a virologically effective antiretroviral regimen, as its use is linked to the detection of higher levels of pro-inflammatory mediators in comparison with INI and NNRTI.

scholarly journals 2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S979-S979
Author(s):  
Christy Comeaux ◽  
Arangassery Rosemary Bastian ◽  
Els De Paepe ◽  
Edmund Omoruyi ◽  
Wouter Haazen ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Neutralizing Antibody ◽  
Severe Illness ◽  
Tolerability Profile ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Antibody Titers ◽  
Group 2 ◽  
Tract Infections ◽  
Group 1

Abstract Background Influenza and RSV can cause respiratory tract infections leading to severe illness, hospitalization and mortality in at-risk populations, particularly the elderly. The seasonality of influenza and RSV present the potential to co-administer vaccines. This study aimed to demonstrate the non-inferiority of co-administration of the experimental RSV vaccine Ad26.RSV.preF with an influenza vaccine (Fluarix) vs. Fluarix alone in terms of immunogenicity against influenza. Methods This was a single-center, randomized, double-blind, placebo-controlled Phase 2a study (NCT03339713) in healthy adults ≥60 years old. Volunteers were randomized 1:1 to receive Fluarix + 1 × 1011 vp Ad26.RSV.preF on Day 1 and placebo on Day 29 (Group 1), or Fluarix + placebo on Day 1 and 1 × 1011 vp Ad26.RSV.preF on Day 29 (Group 2). Blood samples were taken prior to each vaccination and at Day 57. The primary endpoints were geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody titers against Fluarix strains (A/Michigan, A/Hong Kong, B/Brisbane and B/Phuket) and the safety and tolerability of Ad26.RSV.preF administered with or without Fluarix. A key secondary endpoint was neutralizing antibody titers to RSV A2. Results Volunteers (N = 180) were included in Group 1 (n = 90) or Group 2 (n = 90). Most volunteers were white (89%) and female (63%), with a median age of 65 years. Both groups exhibited an increase from baseline in HI antibody response on Day 29. The 95% one-sided upper confidence limit of all GMT ratios were below the non-inferiority margin of 2. The frequency of solicited adverse events (AE) after Ad26.RSV.preF vaccination was similar with and without influenza co-administration. Solicited AEs were mainly of Grade 1 and 2 and of transient duration. Most unsolicited AEs were considered unrelated to the study vaccination and were Grade 1 or 2. There were no serious AEs related to the study vaccine and there were no discontinuations due to AEs. RSV neutralizing antibody titers 29 days post- Ad26.RSV.preF immunization were similar in both groups (1404, Group 1; 1690, Group 2). Conclusion Co-administration of Ad26.RSV.preF with Fluarix was non-inferior to Fluarix alone in terms of immunogenicity against influenza and had an acceptable tolerability profile. Disclosures All authors: No reported disclosures.

scholarly journals 2699. Pneumococcal Vaccination During Chemotherapy in Children Treated for Acute Lymphoblastic Leukemia

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S949-S949
Author(s):  
Sarah Dorval ◽  
Léna Coïc ◽  
Denis Blais ◽  
Jean-Marie Leclerc ◽  
Caroline Laverdière ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Lymphoblastic Leukemia ◽  
Pneumococcal Infection ◽  
Pneumococcal Vaccination ◽  
Booster Vaccination ◽  
Maintenance Phase ◽  
Vaccination Schedule ◽  
Serum Samples ◽  
Group 2 ◽  
Group 1

Abstract Background Children undergoing therapy for acute lymphoblastic leukemia (ALL) are at high risk of invasive pneumococcal disease (IPD). Immunization with conjugated vaccines following chemotherapy is recommended for pediatric patients. In an attempt to provide an earlier protection against invasive pneumococcal infection, we aimed to assess immunity to S. pneumoniae among children vaccinated during chemotherapy for ALL. Methods We retrospectively analyzed the rate of seroprotection among ALL children treated in our institution in accordance with the DFCI ALL Consortium protocol between 2007 and 2014. A pneumococcal conjugate vaccine (PCV) booster was given to all subjects after the end of chemotherapy (groups 1 and 2). In group 2, a PCV dose was also administered during the maintenance phase. Clinical characteristics as well as individual immunization records were collected from our local immunization database. All children were up to date with their vaccination schedule at diagnosis. Serum samples were obtained on a routine follow-up visit, after the end of chemotherapy and after the PCV vaccine booster to measure serotype-specific IgG pneumococcal antibodies. Antibody level ≥0.35µg/mL was considered protective. Patients with seroprotective antibodies level for ≥ 50% of serotypes contained in vaccines were defined as seroprotected. Results 62 children [34 girls (54.8%)] were included in the analysis. Median age at diagnosis was 45 months (range:12–160). At the end of chemotherapy, 34.2% of children in group 1 (13/38) and 79.2% in group 2 (19/24) were seroprotected (P < 0.01). Median interval of time between the end of chemotherapy and the PCV booster vaccination was 6 months (range: 2–64 months). After PCV-13 booster, the rate of seroprotection raised to 100% (38/38) in group 1 and 91.7% in group 2 (22/24). Conclusion Rates of pneumococcal seroprotected children treated for ALL are low at the end of chemotherapy. However, PCV booster during chemotherapy could be useful to increase the level of seroprotection and shorten the period of susceptibility to IPD. After chemotherapy for ALL, children benefit from a PCV booster to enhance seroprotection. Disclosures All authors: No reported disclosures.

scholarly journals Elevated antimeasles antibody titre: An association in autoimmune encephalitis

2015 ◽  
Vol 06 (04) ◽  
pp. 536-540 ◽  
Author(s):  
S. R. Chandra ◽  
Thomas Gregor Issac ◽  
Mariamma Philip ◽  
A. Krishnan
Keyword(s):  
Subacute Sclerosing Panencephalitis ◽  
Autoimmune Encephalitis ◽  
Virus Infections ◽  
Exact Test ◽  
Double Incontinence ◽  
Antibody Positivity ◽  
Antibody Titers ◽  
Clonic Seizures ◽  
Group 2 ◽  
Group 1

ABSTRACT Introduction: Autoimmune encephalitis is a group of treatable noninfective encephalitic disorders with great clinical implications. They have a close resemblance to prion disease and some slow virus infections. We report the presence of significant titers of antimeasles antibody in some of our patients with autoimmune encephalitis resulting in diagnostic and therapeutic problems. Patients and Methods: Patients seen by us in the last 4 years with high titers (1:625 dilution) cerebrospinal fiuid (CSF) antimeasles antibody positivity were reviewed retrospectively. The data collected were assessed using SPSS- Statistical Package for Social Sciences Version 15.0 (IBM corporation) software. The groups which showed elevated antimeasles antibody titers but did not have other parameters suggestive of subacute sclerosing panencephalitis (Group 2) were segregated and compared with those who had the typical features (Group 1) using Fisher's Exact Test. Results: There were 33 patients with antimeasles antibody in CSF. Group 1 had 27 and Group 2 had 6 patients. Group 1 had lower age, cognitive dysfunction, slow myoclonus, less generalized tonic-clonic seizures, and focal seizures. Group 2 patients belonged to the higher age, had significant psychosis (P = 0.02), incontinence of bowel and bladder (P = 0.0001). Slow myoclonus was significant in the first group (P = 0.028), and weakness was significant in the second group (P = 0.028) and double incontinence in the second group (P = 0.0001). Magnetic resonance imaging showed significant gray matter and cerebellar involvement in Group 2 P = 0.005 and P = 0.028, respectively. Conclusions: Patients who show significant titers of antimeasles antibodies in the CSF but belonging to older age group with psychosis, generalized tonic-clonic seizures, double incontinence, focal myoclonus, and electroencephalographic and imaging noncorroborative need to be investigated for autoimmune encephalitis in view of the great prognostic and therapeutic relevance.

A possible cause of the variable detectability of macroprolactin by different immunoassay systems

2016 ◽  
Vol 54 (4) ◽  
Author(s):  
Naoki Hattori ◽  
Kohzo Aisaka ◽  
Akira Shimatsu
Keyword(s):  
Polyethylene Glycol ◽  
Gel Filtration ◽  
Protein G ◽  
Normal Range ◽  
Serum Samples ◽  
Chemiluminescence Immunoassay ◽  
Factors Influencing ◽  
Group 2 ◽  
Possible Cause ◽  
Group 1

AbstractMacroprolactinaemia is a major cause of hyperprolactinaemia. The detectability of macroprolactin varies widely among different immunoassay systems, but the causes are not fully known. This study aimed to identify the factors influencing the detectability of macroprolactin by immunoassay systems.The study included 1544 patients who visited an obstetric and gynaecological hospital. Macroprolactinaemia was screened using the polyethylene glycol (PEG) method and confirmed using gel filtration chromatography and the protein G method. The prolactin (PRL) values determined by enzyme immunoassay (EIA) were compared with those of a chemiluminescence immunoassay system (Centaur) that is known to cross-react the least with macroprolactin.Macroprolactinaemia was found in 62 of 1544 patients (4.02%) who visited an obstetric and gynaecological hospital. The ratio of EIA-determined total PRL to free PRL in the supernatant after PEG precipitation was significantly elevated in all 62 serum samples with macroprolactin compared to those in 1482 serum samples without macroprolactin. In contrast, the ratio of Centaur-determined total PRL to free PRL was significantly elevated in 32 serum samples (group 1) and was within the normal range in 30 (group 2) of 62 serum samples with macroprolactin. The prevalence of non-IgG-type macroprolactin was significantly higher in group 1 than in group 2. Centaur diagnosed hyperprolactinaemia less frequently than EIA (n=2 vs. 16) in 62 patients with macroprolactinaemia. Those two hyperprolactinaemic patients diagnosed by Centaur had non-IgG-type macroprolactin.Macroprolactinaemia was present in 4% of patients visiting an obstetric and gynaecological hospital. The nature of macroprolactin (IgG-type or non-IgG-type) may partly explain why macroprolactin detectability varies among different immunoassay systems.

scholarly journals Increased serum interleukin-9 and interleukin-1β are associated with depression in type 2 diabetes patients

2020 ◽  
Vol 78 (5) ◽  
pp. 255-261 ◽  
Author(s):  
Prabhat VARSHNEY ◽  
Rizwana PARVEEN ◽  
Mohd Ashif KHAN ◽  
Sunil KOHLI ◽  
Nidhi B. AGARWAL
Keyword(s):  
Quality Of Life ◽  
Positive Association ◽  
Diabetic Patients ◽  
Serum Samples ◽  
Type 2 Diabetic Patients ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

ABSTRACT Background: Co-morbid diabetes and depression are prevalent chronic conditions negatively affecting quality of life (QoL). Inflammation has been considered as an integral mechanism in patients with both diabetes and depression. Objective: The aim of the present study was to investigate depression and its association with interleukins (IL)-1β and IL-9 in type 2 diabetic patients (T2DM) and controls. The QoL in diabetic patient was also assessed. Methods: Eighty subjects were included, distributed among three groups: Group 1 - Healthy controls; Group 2 - T2DM patients without depression; Group 3 - T2DM patients with depression. Depression and QoL were assessed using Patient Health Questionnaire (PHQ-9) and The Audit of Diabetes-Dependent QoL (ADDQoL), respectively. IL-1β and IL-9 were measured in serum samples of all the patients using ELISA kit. Results: The PHQ score in the Group 3 was significantly higher as compared to Group 1. The ADDQoL scores in the Group 3 were significantly higher as compared to Group 2. Levels of IL-9 and IL-1β were elevated in Group 3, as compared to the other groups. Conclusion: This study showed positive association between depression and IL-1β, IL-9 in T2DM patients. Additionally, the diabetic patients have poorer quality of life, which is further worsened by the presence of depression. Thus, routine assessment for the presence of depression is suggested in T2DM patients.

scholarly journals Comparative Immunogenicity Evaluation of Two Commonly Used Infectious Bursal Disease Vaccines in Broiler Chickens in Ethiopia

2021 ◽  
Author(s):  
Likelesh Legese ◽  
Berhane Wakjira ◽  
Tsedale Teshome ◽  
Dereje Nigussie Woldemichael ◽  
Hika Waktole ◽  
...  
Keyword(s):  
Broiler Chickens ◽  
Immunological Response ◽  
Elisa Test ◽  
Infectious Bursal Disease ◽  
Differential Leukocyte Count ◽  
Endemic Diseases ◽  
Bursal Disease ◽  
Antibody Titers ◽  
Group 2 ◽  
Group 1

Infectious bursal disease (IBD) is one of the most endemic diseases of commercial poultry in Ethiopia. Vaccination has been practiced as the major means of IBD prevention and control. A study was conducted to determine and compare the immunogenicity of two commercially available IBD vaccines in broiler chicken with maternally derived antibody (MDA). Day-old chickens of 270 were randomly assigned to three groups, group 1 vaccinated with brand 1 vaccine at 7th and 19th days and group 2 with brand 2 vaccine at 15th and 22nd days while group 3 were kept as control. Six chickens were also randomly selected and bled on day 1 for differential leukocyte count (DLC) and determination of MDA. Representative chickens from each group were bled at 24th and 42nd days of age for antibody titration using the indirect ELISA test. DLC scores were determined in the 1st and 24th days. The result revealed highly significant differences (P = 0.001) between group 1 and group 2 in DLC at 24th days of age. Antibody titers against IBD were differed significantly (P = 0.02) at 24th and 42nd days of age in broilers vaccinated with brand 1 and brand 2 vaccines. It is concluded that although both brands of vaccine induce an adequate immunological response at the end of the experiment, brand 1 vaccine has shown significantly high antibody titers against the IBDV and DLC than brand 2.

scholarly journals Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity?

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Marta Tonello ◽  
Elisa Bison ◽  
Maria Grazia Cattini ◽  
Elena Pontara ◽  
Luca Iaccarino ◽  
...  
Keyword(s):  
Antiphospholipid Syndrome ◽  
Lupus Anticoagulant ◽  
Phosphatidyl Serine ◽  
Positive Test ◽  
Clotting Time ◽  
Glycoprotein I ◽  
Coagulation Tests ◽  
Group 2 ◽  
Positive Results ◽  
Group 1

Abstract Objectives Anti phosphatidylserine/prothrombin antibodies (aPS/PT) are often present in patients with antiphospholipid syndrome (APS) and might be relevant in the pathogenesis of this condition. They are major determinant of lupus anticoagulant (LA) in triple-positive antiphospholipid (aPL) profile. Whether they are present and pathogenic in patients with isolated LA [negative anticardiolipin (aCL) and anti β2-Glycoprotein I (aβ2GPI) antibodies] is a matter of debate. Methods We measured aPS/PT in a large number of isolated LA with the aim to ascertain whether there is a link between the way isolated LA is assessed and the presence of these antibodies. APS/PT were measured in 86 patients with isolated LA (aCL- and abeta2GPI-). LA was assessed by two test systems, the dilute Russell Viper Venom Time (dRVVT) and the Silica Clotting Time (SCT). Results Sixty-six (77%) individuals with isolated LA were positive for aPS/PT (IgM 44, IgG and IgM 15, IgG in 7). Diagnosis of LA was made based on positive results in both dRVVT and SCT in 40 patients (Group 1) and based on only one positive test in the remaining 46 patients (Group 2). The rate of positive aPS/PT antibodies was significantly higher in Group 1 (OR=7.2, 95% CI 1.9–27.0, p<0.002). Moreover, the titre of IgM aPS/PT was significantly increased in Group 1 as compared to Group 2 (137 U, IQR 64–179 vs. 43 U, IQR 11–120, p=0.008). Conclusions These data indicate an association between LA based on two positive coagulation tests and the presence of aPS/PT antibodies, especially of IgM isotype.

SEROLOGICAL DIAGNOSIS OF PERTUSSIS IN OLDER PERSONS

2020 ◽  
Vol 65 (8) ◽  
pp. 492-495
Author(s):  
T. A. Skirda ◽  
O. Yu. Borisova ◽  
M. S. Petrova ◽  
A. B. Borisova ◽  
S. Yu. Kombarova
Keyword(s):  
Blood Serum ◽  
Threshold Level ◽  
Test System ◽  
Serum Samples ◽  
Pertussis Infection ◽  
Diagnostic Center ◽  
Group 2 ◽  
Definition Of ◽  
Level Group ◽  
Group 1

The aim of the work was to assess the effectiveness of serodiagnosis of pertussis in people over 50 who complained of prolonged cough. The study included 30 patients over the age of 50 who applied to the consultative diagnostic center complaining of a prolonged cough in the period from 2015 - 2020. Blood serum samples were investigated in enzyme immunoassay with the definition of antitussive antibodies of three classes - IgM, IgG, IgA in the commercial test system RIDASCREEN (R-Biopharm AG, Germany). It was found that in the serum samples of individuals over the age of 50, IgM antibodies above the threshold level were not detected. Patients were divided into two groups - with IgG and IgA antibodies above the threshold level (group 1) and below the threshold level (group 2). In the first group, in 83.3% and 61.1% of patients, the levels of antibodies of the IgG and IgA class significantly exceeded the threshold level (189.8 ± 16.7 U / ml and 290 ± 20 U / ml, respectively), which indicated a pertussis infection; in 5.6% and 38.9% of patients, IgG and IgA class antibodies slightly exceeded the threshold level (20 U / ml and 43 ± 2.3 U / ml, respectively), which indicated a dying infection. In the second group, in 100% of patients, antibodies of the IgM and IgA classes were determined below threshold levels, and IgG antibodies were detected in 58.3% of individuals at low rates, which corresponded to the natural immunological background of individuals not infected with pertussis pathogen. Therefore, in the presence of a prolonged cough in adults, it is advisable to study blood serum samples for the presence of antitussive antibodies of three classes, which is especially important when people of older age live in families with young children and pregnant women

scholarly journals The effect of curcumin on lipid peroxidation and selected antioxidants in irradiated rats

2018 ◽  
Vol 87 (4) ◽  
pp. 379-385 ◽  
Author(s):  
Mehtap Ozcelik ◽  
Mine Erişir ◽  
Osman Guler ◽  
Murat Baykara ◽  
Esra Kirman
Keyword(s):  
Lipid Peroxidation ◽  
Superoxide Dismutase ◽  
Body Weight ◽  
Glutathione Peroxidase ◽  
Control Group ◽  
Sod Activity ◽  
Irradiation Group ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

The effect of irradiation on oxidants and antioxidants in selected tissues and a possible protective effect of curcumin on these indices were investigated. A total of 28 rats were divided into 3 groups; group 1 was control; group 2 was the irradiation group, saline was administered intraperiotenally (i.p.) for three days and then, 9 Gy gamma irradiation was applied; group 3 was the irradiation + curcumin group: curcumin was given i.p. for three days at 200 mg/kg body weight and then the same dose of irradiation was applied. A significant increase in malondialdehyde (MDA) was detected in the liver, kidney, and brain tissues of the rats as a result of irradiation (P< 0.01). Glutathione peroxidase (GSH-Px) activity in all the tissues (except for kidneys) decreased (P< 0.01), liver SOD (superoxide dismutase) activity decreased (P< 0.05), and GSH (glutathione) levels in kidney and ovary tissues (P< 0.001) significantly increased. While curcumin administration returned the increased MDA levels in the kidneys and brain in result of irradiation to normal (P< 0.01), it did not return the increased MDA levels in the liver tissue to normal (P< 0.001) despite significantly reducing them. While decreased GSH-Px and SOD activity in the liver in result of irradiation increased with the addition of curcumin (P< 0.05), increased GSH levels in the kidneys and ovaries returned to control levels (P< 0.001). When MDA values were examined, it was found that the addition of curcumin protected the liver, kidneys and brain from the oxidative damage caused by irradiation.

Sign in / Sign up

Export Citation Format

Share Document